Skip to main content
SpringerLink
Log in

Treatment Strategies in Children with Hemophilia

  • Therapy In Practice
  • Published:
Pediatric Drugs Aims and scope Submit manuscript

Abstract

Hemophilia is an inherited bleeding disorder caused by quantitative or qualitative defects in the synthesis of factor VIII (FVIII) or factor IX (FIX). Clinically, it is divided into severe, moderate and mild disease depending on the levels of FVIII or FIX in the blood. The bleeding tendency is most pronounced and can start at a very young age in severe hemophilia, which is characterized by repeated hemorrhage into the joints and muscles. Without treatment, these episodes lead to severe arthropathy, and there is also a high risk of lethal cerebral hemorrhage.

The treatment of bleeding symptoms requires the correction of the coagulation defect. Factor concentrates have been available for 30 years, initially with the development of cryoprecipitate, subsequently with increasingly purified plasma-derived forms, and ultimately with recombinant clotting factor concentrates. The advantage of this highly effective therapy has been subdued by the outbreak of HIV and Hepatitis C infections in patients with hemophilia treated with factor concentrates which did not have adequate viral inactivation steps in the purification process. Plasma-derived and recombinant factor concentrates are today considered to have a good safety profile, but are only available for a small group of hemophilia patients worldwide.

A multidisciplinary team approach is important for early diagnosis, communication with the patient and parents, and to tailor the best treatment possible with the amount of clotting factor concentrates available. The main goal of hemophilia treatment is to prevent bleeding symptoms and allow normal integration in social life. In patients with severe hemophilia, this can best be achieved by early home treatment and primary prophylaxis. Future developments in gene therapy may transform severe hemophilia to a mild form, with no need for regular injections of clotting factor concentrates.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Fig. 2
Table II
Table III
Table IV

Similar content being viewed by others

Notes

  1. The use of tradenames is for product identification only and does not imply endorsement.

References

  1. Ljung R, Kling S, Sjörin E, et al. More than half the sporadic cases of haemophilia A in Sweden are due to a recent mutation. Acta Paediatr Scand 1991; 80: 343–8

    Article  PubMed  CAS  Google Scholar 

  2. Gitschier J, Wood WI, Goralka TM, et al. Characterisation of human factor VIII gene. Nature 1984; 312: 326–30

    Article  PubMed  CAS  Google Scholar 

  3. Toole JJ, Knopf JL, Wozney JM, et al. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 1984; 312: 342–7

    Article  PubMed  CAS  Google Scholar 

  4. Choo KH, Gould KG, Rees DJG, et al. Molecular cloning of the gene for human anti-haemophilia factor IX. Nature 1982; 299: 178–80

    Article  PubMed  CAS  Google Scholar 

  5. Lakich D, Kazazian HH, Antonarakis SE, et al. Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A. Nat Genet 1993; 5: 236–41

    Article  PubMed  CAS  Google Scholar 

  6. Naylor J, Brinke A, Hassock S, et al. Characteristic mRNA abnormality found in half of the patients with severe haemophilia A is due to large DNA inversions. Hum Mol Genet 1993; 11: 1773–8

    Article  Google Scholar 

  7. Peake IR, Lillicrap DP, Boulyjenkov V, et al. Haemophilia: strategies for carrier detection and prenatal diagnosis. Bull World Health Organ 1993; 71: 429–58

    PubMed  CAS  Google Scholar 

  8. Tuddenham FGD, Goldman E, McGraw A, et al. Haemophilia A: carrier detection and prenatal diagnosis by linkage analysis using DNA polymorphism. J Clin Pathol 1987; 40: 971–7

    Article  PubMed  CAS  Google Scholar 

  9. Goodeve AC, Peake IR. Diagnosis of haemophilia A carriers and prenatal diagnosis. In: Forbes CD, Aledort L, Madhok R, editors. Hemophilia. London: Chapman & Hall, 1997: 63–74

    Google Scholar 

  10. Dardik R, Peretz H, Usher S, et al. Current strategy for genetic analysis of haemophilia A families. Haemophilia 1996; 2: 11–7

    Article  Google Scholar 

  11. Peake IR, Lillicrap DP, Boulyjenkov V, et al. Report of a joint WHO/WFH meeting on the control of haemophilia: carrier detection and prenatal diagnosis. Blood Coagul Fibrinolysis 1993; 4: 313–44

    Article  PubMed  CAS  Google Scholar 

  12. Miller R. Counselling about diagnosis and inheritance of genetic bleeding disorders: haemophilia A and B. Haemophilia 1999; 5: 77–83

    Article  PubMed  CAS  Google Scholar 

  13. Tedgård U, Ljung R, McNeil T. How do carriers of haemophilia experience prenatal diagnosis (PND): carrier’s immediate and later reactions to amniocentesis and fetal blood sampling. Acta Paediatr Scand 1989; 78: 692–700

    Article  PubMed  Google Scholar 

  14. Janco RL, MacLean WE, Perrin JM, et al. A prospective study of patterns of bleeding in boys with haemophilia. Haemophilia 1996; 2: 202–6

    Article  Google Scholar 

  15. Ljung R, Petrini P, Nilsson IM. Diagnostic symptoms of severe and moderate haemophilia A and B: a survey of 140 cases. Acta Paediatr Scand 1990; 79: 196–200

    Article  PubMed  CAS  Google Scholar 

  16. Smith PS, Keyes NC, Forman EN. Socioeconomic evaluation of a state-funded comprehensive haemophilia-care program. N Engl J Med 1982; 306: 575–9

    Article  PubMed  CAS  Google Scholar 

  17. Soucie JM, Symons IVJ, Evatt B, et al. Home-based factor infusion therapy and hospitalisation for bleeding complications among males with haemophilia. Haemophilia 2001; 7: 198–206

    Article  PubMed  CAS  Google Scholar 

  18. Smith PS, Levine PH. The benefits of comprehensive care of haemophilia: a five-year study of outcomes. Am J Public Health 1984; 74: 616–7

    Article  PubMed  CAS  Google Scholar 

  19. Mariani G. The Haemophilia Centre twinning programme. Haemophilia 1996; 2: 125–7

    Article  Google Scholar 

  20. Jones P. Haemophilia: a global challenge. Haemophilia 1995; 1: 11–3

    Article  Google Scholar 

  21. Rodriguez-Merchan EC. Pathogenesis, early diagnosis, and prophylaxis for chronic haemophilic synovitis. Clin Orthop 1997; 343: 6–11

    PubMed  Google Scholar 

  22. Stein H, Duthie RB. The pathogenesis of chronic haemophilic synovitis. J Bone Joint Surg Br 1981; 63B: 601–9

    PubMed  CAS  Google Scholar 

  23. Roosendaal G, Vianen ME, Wenting MJG, et al. Iron deposits and catabolic properties of synovial tissue of patients with haemophilia. J Bone Joint Surg Br 1998; 80: 540–5

    Article  PubMed  CAS  Google Scholar 

  24. Roosendaal G, Vianen ME, van der Berg HM, et al. Cartilage damage as a result of hemarthrosis in a human in vitro model. J Rheumatol 1997; 24: 1350–4

    PubMed  CAS  Google Scholar 

  25. Rodriguez-Merchan EC. Effects of haemophilia on articulations of children and adults. Clin Orthop 1996; 328: 7–13

    Article  PubMed  Google Scholar 

  26. Roosendaal G, de Kleijn P, Mauser-Bunschoten EP, et al. Treatment of chronic synovitis. In: Heijnen L, editor. Recent advances in rehabilitation in haemophilia. Sussex: Medical Education Network, 1996

    Google Scholar 

  27. Molho P, Verrier P, Stieltjes N, et al. A retrospective study on chemical and radioactive synovectomy in severe haemophilia patients. Haemophilia 1999; 5: 115–23

    Article  PubMed  CAS  Google Scholar 

  28. Rodriguez Merchan EC, Caviglia H, Magallon M, et al. Chemical synovectomy versus radioactive synovectomy for treatment of chronic haemophilic synovitis: a prospective short term study. Haemophilia 1997; 3: 118–22

    Article  Google Scholar 

  29. Nelson Jr MD, Maeder MA, Usner D, et al. Prevalence and incidence of intracranial haemorrhage in a population of children with haemophilia. Haemophilia 1999; 5: 306–12

    Article  PubMed  Google Scholar 

  30. Boone DC. Management of musculo-skeletal problems of haemophilia. Phys Ther 1974; 54: 123–7

    Google Scholar 

  31. Buzzard BM. Sports and haemophilia: antagonist or protagonist. Clin Orthop 1996; 328: 25–30

    Article  PubMed  Google Scholar 

  32. Jones PM, Buzzard BM, Heinmen L. Go for it: guidelines on physical activity and sports for people with haemophilia and related diseases. Montreal (QC): World Federation of Haemophilia, 1998

    Google Scholar 

  33. Kasper CK, Lusher JM. Recent evaluation of clotting factor concentrates for haemophilia A and B. Transfusion Practices Committee. Transfusion 1993; 33: 422–33

    Article  PubMed  CAS  Google Scholar 

  34. Lusher JM, Arkin S, Abildgaard CF, et al. Recombinant factor VIII for the treatment of previously untreated patients with haemophilia A. N Engl J Med 1993; 328: 453–9

    Article  PubMed  CAS  Google Scholar 

  35. Brackmann HH, Egil H. Acute hepatitis B infection after treatment with heat-inactivated factor VIII concentrate [letter]. Lancet 1988; II: 967

    Article  Google Scholar 

  36. White II GC, Shapiro AD, Ragni MV, et al. A pharmacokinetic evaluation of recombinant human factor IX (rhFIX) in patients with severe haemophilia B [abstract no. 437]. Thromb Haemost 1995; 73: 1014

    Google Scholar 

  37. Srivastava A. Factor replacement for haemophilia: should cryoprecipitate be used. Haemophilia 1999; 5: 301–5

    Article  PubMed  CAS  Google Scholar 

  38. Ferguson M, Minor PD, Garrett AJ, et al. Testing plasma pools for markers of viral contamination: the UK experience. Vox Sang 1996; 71: 21–6

    Article  PubMed  CAS  Google Scholar 

  39. Shapiro AD, Ragni MV, Lusher JM, et al. Safety and efficacy of monoclonal antibody purified factor IX concentrate in previously untreated patients with haemophilia B. Thromb Haemost 1996; 75: 30–5

    PubMed  CAS  Google Scholar 

  40. Mannucci PM, Schimpf K, Abe T, et al. Low risk of viral infection after administration of vapor-heated factor VIII concentrate. Transfusion 1992; 32: 134–8

    Article  PubMed  CAS  Google Scholar 

  41. Mannucci PM. Modern treatment of haemophilia: from the shadows towards the light. Thromb Haemost 1993; 70(1): 17–23

    PubMed  CAS  Google Scholar 

  42. Santagostino E, Mannucci PM, Gringeri A, et al. Eliminating parvovirus B19 from blood products [letter]. Lancet 1994; 343: 798

    Article  PubMed  CAS  Google Scholar 

  43. Mannucci PM, Gdovin S, Gringeri A, et al. Transmission of hepatitis A to patients with haemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. Ann Intern Med 1994; 120: 1–7

    PubMed  CAS  Google Scholar 

  44. Lawlor E, Johnson Z, Thornton L, et al. Investigation of an outbreak of hepatitis A in Irish haemophilia A patients. Vox Sang 1994; 67Suppl. 1: 18–20

    Article  PubMed  Google Scholar 

  45. Klein R, Dumble LJ. Transmission of Creutzfeldt-Jakob disease by blood transfusion [letter]. Lancet 1993; 341: 768

    Article  PubMed  CAS  Google Scholar 

  46. Björkman S, Carlsson M. The pharmacokinetics of factor VIII and factor IX: methodology, pitfalls and applications. Haemophilia 1997; 3: 1–8

    Article  Google Scholar 

  47. Manucci PM, Canciani MT, Rota L, et al. Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects, and patients with haemophilia A and von Willebrand’s disease. Br J Haematol 1981; 47: 283–93

    Article  Google Scholar 

  48. Manucci PM, Vicente V, Alberca I, et al. Intravenous and subcutaneous administration of desmopressin (DDAVP) to haemophiliacs: pharmacokinetics and factor VIII responses. Thromb Haemost 1987; 58: 1037–9

    Google Scholar 

  49. Lethagen S, Ragnarson-Tenvall G. Self-treatment with desmopressin intranasal spray in patients with bleeding disorders: effect on bleeding symptoms and socioeconomic factors. Ann Hematol 1993; 66: 257–60

    Article  PubMed  CAS  Google Scholar 

  50. Liesner RJ, Vora AJ, Hann IM, et al. Use of central venous catheters in children with severe cogenital coagulopathy. Br J Haematol 1995; 91: 203–7

    Article  PubMed  CAS  Google Scholar 

  51. Ljung R, Petrini P, Lindgren AK, et al. Implantable central venous catheter facilitates prophylactic treatment in children with haemophilia. Acta Paediatr 1992; 81: 918–20

    Article  PubMed  CAS  Google Scholar 

  52. Ljung R, van den Berg M, Petrini P, et al. Port-á-Cath usage in children with haemophilia: experience of 53 cases. Acta Paediatr 1998; 87: 1051–4

    Article  PubMed  CAS  Google Scholar 

  53. Vidler V, Richards M, Vora A. Central venous catheter-associated thrombosis in severe haemophilia. Br J Haematol 1996; 104(3): 461–4

    Article  Google Scholar 

  54. Nilsson IM, Hedner U, Ahlberg Å. Haemophilia prophylaxis in Sweden. Acta Paediatr Scand 1976; 65: 129–35

    Article  PubMed  CAS  Google Scholar 

  55. Petrini P, Blombäck M, Lindvall N. Prophylaxis with factor concentrates in preventing haemophilic arthropathy. Am J Paediatr Haematol Oncol 1991; 13: 280–7

    Article  CAS  Google Scholar 

  56. Ahlberg Å. Haemophilia in Sweden, VII: incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand 1965; Suppl. 77: 3–132

    Google Scholar 

  57. Kreutz W, Escuriola-Ettingshausen C, Funk M, et al. When should prophylactic treatment in patients with haemophilia A and B start: the German experience. Haemophilia 1998; 4: 413–7

    Article  Google Scholar 

  58. Petrini P. What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B. Haemophilia 2001; 7: 99–102

    Article  PubMed  CAS  Google Scholar 

  59. Astermark J, Petrini P, Tengbom L, et al. Primary prophylaxis in severe haemophilia should be started early but can be individualised. Br J Haematol 1999; 105: 1109–13

    Article  PubMed  CAS  Google Scholar 

  60. Blanchette VS, al-Musa A, Stain AM, et al. Central venous access catheters in children with haemophilia. Blood Coagul Fibrinolysis 1996; 7Suppl. 1: S39–44

    PubMed  Google Scholar 

  61. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994; 236: 391–9

    Article  PubMed  CAS  Google Scholar 

  62. Nilsson IM, Berntorp E, Löfqvist T, et al. Twenty five years’ experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25–32

    Article  PubMed  CAS  Google Scholar 

  63. Fischer K, Van Der Bom JG, Prejs R, et al. Discontinuation of prophylactic therapy in severe haemophilia incidence and effects on outcome. Haemophilia 2001; 7(6): 544–50

    Article  PubMed  CAS  Google Scholar 

  64. Carlsson M, Berntorp E, Björkman P, et al. Pharmacokinetic dosing in prophylactic treatment of haemophilia A. Eur J Haematol 1993; 51: 247–52

    Article  PubMed  CAS  Google Scholar 

  65. Rosendaal FR, Smit C, Varekamp I, et al. Modern haemophilia treatment: medical improvements and quality of life. J Intern Med 1990; 228: 633–40

    Article  PubMed  CAS  Google Scholar 

  66. Manco-Johnson MJ, Nuss R, Geraghty S, et al. Results of secondary prophylaxis in children with severe haemophilia. Am J Haematol 1994; 47: 113–7

    Article  CAS  Google Scholar 

  67. Fischer K, van der Berg JG, Mauser-Bunschoten EP, et al. Changes in treatment for haemophilia over the last 30 years. Haemophilia 2000; 6(4): 272–3

    Google Scholar 

  68. Schulman S, Varon D, Keller N, et al. Monoclonal purified F VIII for continuous infusion: stability, microbiological safety and clinical experience. Thromb Haemost 1994; 72: 403–7

    PubMed  CAS  Google Scholar 

  69. Schulman S, Gitel S, Zivelin A, et al. The feasibility of using concentrates containing factor IX for continuous infusion. Haemophilia 1995; 1: 103–10

    Article  Google Scholar 

  70. Rodriguez-Merchan EC. Management of orthopaedic complications of haemophilia. J Bone Joint Surg Br 1998; 80B: 191–6

    Google Scholar 

  71. Philips AM, Sabin CA, Ribbans WJ, et al. Orthopaedic surgery in haemophilic patients with human immunodeficiency virus. Clin Orthop 1997; 343: 81–7

    Google Scholar 

  72. Wiedel JD, Luck JV, Gilbert MS. Total knee arthroplasty in the patient with haemophilia: evaluation and long-term results. In: Gilbert MS, Greene WB, editors. Musculoskeletal problems in haemophilia. New York: National Haemophilia Fundation, 1989: 152–7

    Google Scholar 

  73. Löfqvist T, Nilsson IM, Petersson C. Orthopaedic surgery in haemophilia: 20 years’ experience in Sweden. Clin Orthop 1996; 332: 232–41

    Article  PubMed  Google Scholar 

  74. Ehrenforth S, Kreutz W, Scharrer I, et al. Incidence of development of factor VIII and IX inhibitors in haemophiliacs. Lancet 1992; 339: 594–8

    Article  PubMed  CAS  Google Scholar 

  75. Addiego J, Kasper CK, Abildgaard C, et al. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII. Lancet 1993; 342: 462–4

    Article  PubMed  CAS  Google Scholar 

  76. Scharrer I, Bray GL, Neutzling O. Incidence of inhibitors in haemophilia A patients: a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia 1999; 5: 145–54

    Article  PubMed  CAS  Google Scholar 

  77. Warrier I, Ewenstein BM, Koerper MA, et al. Factor IX inhibitors and anaphylaxis in haemophilia B. J Paediatr Haematol Oncol 1997; 19: 23–7

    Article  CAS  Google Scholar 

  78. Hedner U, Glazer S. Management of haemophilia patients with inhibitors. Hematol Oncol Clin North Am 1992; 6: 1035–6

    PubMed  CAS  Google Scholar 

  79. Hedner U, Glazer S, Falch J. Recombinant activated factor VII in the treatment of bleeding episodes in patients with inherited acquired bleeding disorders. Transfus Med Rev 1993; 7: 78–83

    Article  PubMed  CAS  Google Scholar 

  80. Lusher JM, Shapiro SS, Palascek JE, et al. Efficacy of prothrombin complex concentrates in haemophiliacs with antibodies to factor VIII. N Engl J Med 1980; 303: 421–5

    Article  PubMed  CAS  Google Scholar 

  81. Brackmann HH. Induced immunotolerance in factor VIII inhibitor patients. Prog Clin Biol Res 1984; 150: 181–95

    PubMed  CAS  Google Scholar 

  82. Oldenburg J, Schwaab R, Brackmann HH. Induction of immune tolerance in haemophilia A inhibitor patients by the ‘Bonn Protocol’: predictive parameter for therapy duration and outcome. Vox Sang 1999; 77Suppl. 1: 49–54

    Article  PubMed  CAS  Google Scholar 

  83. Mauser-Bunschoten EP, Nieuwenhuis HK, Roosendaal G, et al. Low dose immune tolerance induction in haemophilia A patients with inhibitors. Blood 1995; 86(3): 983–8

    PubMed  CAS  Google Scholar 

  84. Van Leeuwen EF, Mauser-Bunschoten EP, van Dijken PJ, et al. Disappearance of factor VIII:C antibodies in patients with haemophilia upon frequent administration of factor VIII in intermediate or low dose. Br J Haematol 1986; 64: 291–7

    Article  PubMed  Google Scholar 

  85. Nilsson IM, Berntorp E, Zettervall O. Induction of immune tolerance in patients with haemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide and factor VIII. N Engl J Med 1988; 318: 947–50

    Article  PubMed  CAS  Google Scholar 

  86. Freiburghaus C, Berntrop E, Ekman M, et al. Immunoadsorption for removal of inhibitors: update on treatments in Malmo-Lund between 1980 and 1995. Haemophilia 1998; 4(1): 16–20

    Article  PubMed  CAS  Google Scholar 

  87. Lenk H, Bierback U, Schille R. Inhibitor to FIX in haemophilia B and nephrotic syndrome in the course of immune tolerance treatment. Haemophilia 1996; 2Suppl. 1: 104

    Google Scholar 

Download references

Acknowledgements

The author wishes to thank Gunilla Klemenz, a nurse in the Coagulation Department for children, Karolinska Hospital, for her support and engagement in our patients and my work.

Author information

Authors and Affiliations

  1. Coagulation Department, Karolinska Hospital, Stockholm, S-171 76, Sweden

    Pia Petrini

Authors
  1. Pia Petrini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pia Petrini.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Petrini, P. Treatment Strategies in Children with Hemophilia. Pediatr-Drugs 4, 427–437 (2002). https://doi.org/10.2165/00128072-200204070-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128072-200204070-00002

Keywords

Search

Navigation